• Explore /
  • Poster
  • / ARTO trial: Overall survival analysis from a randomized phase II trial testing the benefit of adding stereotactic body radiotherapy to abiraterone acetate in patients with oligometastatic castrate-resistant prostate cancer.

ARTO trial: Overall survival analysis from a randomized phase II trial testing the benefit of adding stereotactic body radiotherapy to abiraterone acetate in patients with oligometastatic castrate-resistant prostate cancer.

Abstract Poster

Authors

null

Giulio Francolini

Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy

Giulio Francolini , Vanessa Di Cataldo , Pietro Garlatti , Beatrice Detti , Saverio Caini , Alessio Bruni , Gianluca Ingrosso , Rolando Maria D'Angelillo , Anna Rita Alitto , Matteo Augugliaro , Luca Triggiani , Silvana Parisi , Gaetano Facchini , Marco Banini , Gabriele Simontacchi , Isacco Desideri , Icro Meattini , Richard K. Valicenti , Lorenzo Livi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03449719

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 132)

DOI

10.1200/JCO.2024.42.4_suppl.132

Abstract #

132

Poster Bd #

F3

Abstract Disclosures

Similar Posters

First Author: Giulio Francolini

First Author: Giulio Francolini

First Author: Giulio Francolini

First Author: Henrik Gronberg